India's Risk-Based Inspection Plan: Well Begun?
Executive Summary
India's Central Drugs Standard Control Organization (CDSCO) is taking definitive steps to strengthen the regulatory regime and enforcement, including across areas such as data integrity, in the backdrop of industry's patchy manufacturing compliance story. The regulator has developed risk-based inspection criteria for manufacturing sites, backed by a comprehensive draft checklist and evaluation tool but the real test may lie in resolute implementation.
You may also be interested in...
Indian CEOs On Plugging Quality Gaps: Yes We Can
The top bosses of six leading Indian firms were unequivocal that there is room for improvement on the quality front at a recent conference in Mumbai, but they also emphasized senior management engagement and resolve to get a "quality movement" going in their respective firms and in the domestic industry, in general.
EY India data integrity survey flags gaps, missing processes
An EY (formerly Ernst & Young) survey around data integrity compliance issues within the Indian pharmaceutical sector has thrown up some potentially worrisome findings, including an absence of quality processes and procedures at some firms amid work pressure and manpower shortages.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.